A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II
Tóm tắt
Fluoroquinolones are broad-spectrum antimicrobial agents that target type II topoisomerases. Many fluoroquinolones are highly specific for bacterial type II topoisomerases and act against both DNA gyrase and topoisomerase IV. In
Từ khóa
Tài liệu tham khảo
Beck, W. T., T. Khelifa, H. Kusumoto, Y. Y. Mo, Q. Rodgers, J. S. Wolverton, and Q. Wang. 1997. Novel mechanisms of resistance to inhibitors of DNA topoisomerases. Adv. Enzyme Regul.37:17-26.
Capranico, G., and M. Binaschi. 1998. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta1400:185-194.
Capranico, G., G. Giaccone, F. Zunino, S. Garattini, and M. D'Incalci. 1997. DNA topoisomerase II poisons and inhibitors. Cancer Chemother. Biol. Response Modif.17:114-131.
Capranico, G., F. Zunino, K. W. Kohn, and Y. Pommier. 1990. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry29:562-569.
Chatterji, M., S. Unniraman, S. Mahadevan, and V. Nagaraja. 2001. Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis. J. Antimicrob. Chemother.48:479-485.
Chen, F. J., and H. J. Lo. 2003. Molecular mechanisms of fluoroquinolone resistance. J. Microbiol. Immunol. Infect.36:1-9.
Cozzarelli N. C. and J. C. Wang (ed.). 1990. DNA topology and its biological effects. Cold Spring Harbor Laboratory Cold Spring Harbor N.Y.
Dong, J., J. Walker, and J. L. Nitiss. 2000. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons. J. Biol. Chem.275:7980-7987.
Drlica, K. 1999. Refining the fluoroquinolones. ASM News65:410-415.
Elsea, S. H., N. Osheroff, and J. L. Nitiss. 1992. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem.267:13150-13153.
Elsea, S. H., M. Westergaard, D. A. Burden, J. P. Lomenick, and N. Osheroff. 1997. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry36:2919-2924.
Fass, D., C. E. Bogden, and J. M. Berger. 1999. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat. Struct. Biol.6:322-326.
Heisig, P., and B. Wiedemann. 2001. Action and reaction. Actions and resistance mechanisms of quinolone. Pharm. Unserer Zeit.30:382-393.
Hsiung, Y., S. H. Elsea, N. Osheroff, and J. L. Nitiss. 1995. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors. J. Biol. Chem.270:20359-20364.
Leteurtre, F., D. L. Sackett, J. Madalengoitia, G. Kohlhagen, T. MacDonald, E. Hamel, K. D. Paull, and Y. Pommier. 1995. Azatoxin derivatives with potent and selective action on topoisomerase II. Biochem. Pharmacol.49:1283-1290.
Liu L. 1994. DNA Topoisomerases: topoisomerase-targeting drugs. Academic Press Inc. New York N.Y.
Martinez, J. L., A. Alonso, J. M. Gomez-Gomez, and F. Baquero. 1998. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? J. Antimicrob. Chemother.42:683-688.
National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa.
Nitiss, J. L., and W. T. Beck. 1996. Antitopoisomerase drug action and resistance. Eur. J. Cancer32A:958-966.
Pommier, Y., G. Capranico, A. Orr, and K. W. Kohn. 1991. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res.19:5973-5980. (Erratum, 19:7003.)
Pommier, Y., F. Goldwasser, and D. Strumberg. 2001. Topoisomerase II inhibitors: epipodophyllotoxins, acridines, ellipticines, and bisdioxopiperazines, p. 538. In B. A. Chabner and D. L. Longo (ed.), Cancer chemotherapy and biotherapy: principles and practice, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
Sanders, C. C. 1990. Microbiology of fluoroquinolones, p. 1-28. In W. E. Sanders, Jr., and C. C. Sanders (ed.), Fluoroquinolones in the treatment of infectious diseases. Physicians and Scientists Publishing, Glenview, Ill.
Sanders, C. C., and W. E. Sanders, Jr. 1995. Resistance to antibacterial agents, p. 15-23. In D. L. Jungkind, J. E. Mortensen, H. F. Fraimow, and G. D. Calandra (ed.), Antimicrobial resistance: a crisis in health care. Plenum Press, New York, N.Y.
Strumberg, D., J. L. Nitiss, J. Dong, K. W. Kohn, and Y. Pommier. 1999. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions. J. Biol. Chem.274:28246-28255.
Strumberg, D., J. L. Nitiss, A. Rose, M. C. Nicklaus, and Y. Pommier. 1999. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions. J. Biol. Chem.274:7292-7301.
Tanizawa, A., K. W. Kohn, and Y. Pommier. 1993. Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res.21:5157-5166.